|Mr. Elias Vamvakas||Exec. Chairman and Sec.||231.51k||N/A||58|
|Mr. Joseph S. Jensen||Chief Exec. Officer, Pres and Director||571.93k||N/A||45|
|Mr. Wes Brazell||Chief Financial Officer||364.73k||N/A||51|
|Dr. Richard L. Lindstrom M.D.||Scientific Advisor and Independent Director||36k||N/A||69|
|Dr. Paul M. Karpecki OD, FAAO||Scientific Advisor, Independent Director and Member of Clinical Advisory Board||36k||N/A||50|
TearLab Corporation operates as an in-vitro diagnostic company in the United States. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease. The companys system enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, which is a single-use microfluidic microchip; TearLab pen, which is a hand-held device that interfaces with the TearLab disposable; and TearLab reader, which is a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.
TearLab Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.